Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 138,602 shares of the stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $16.20, for a total value of $2,245,352.40. Following the transaction, the chief executive officer directly owned 1,504,959 shares in the company, valued at $24,380,335.80. The trade was a 8.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Eric Venker also recently made the following trade(s):
- On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The stock was sold at an average price of $16.34, for a total value of $2,800,610.64.
- On Tuesday, October 7th, Eric Venker sold 355,161 shares of Roivant Sciences stock. The stock was sold at an average price of $16.15, for a total value of $5,735,850.15.
- On Tuesday, September 23rd, Eric Venker sold 611,000 shares of Roivant Sciences stock. The stock was sold at an average price of $14.83, for a total value of $9,061,130.00.
- On Monday, September 22nd, Eric Venker sold 416,182 shares of Roivant Sciences stock. The stock was sold at an average price of $14.99, for a total value of $6,238,568.18.
- On Friday, September 19th, Eric Venker sold 683,818 shares of Roivant Sciences stock. The stock was sold at an average price of $14.95, for a total value of $10,223,079.10.
- On Wednesday, August 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.72, for a total value of $1,172,000.00.
- On Monday, July 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.52, for a total value of $1,152,000.00.
Roivant Sciences Price Performance
Roivant Sciences stock traded down $0.09 during midday trading on Wednesday, reaching $16.03. The company's stock had a trading volume of 5,850,620 shares, compared to its average volume of 9,553,693. The stock's 50-day simple moving average is $13.26 and its 200-day simple moving average is $11.71. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $16.79. The stock has a market capitalization of $10.95 billion, a P/E ratio of -22.90 and a beta of 1.20.
Institutional Trading of Roivant Sciences
Institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC grew its holdings in Roivant Sciences by 80.5% in the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock valued at $25,000 after purchasing an additional 1,108 shares during the period. CWM LLC grew its holdings in Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company's stock valued at $34,000 after purchasing an additional 920 shares during the period. UMB Bank n.a. grew its holdings in Roivant Sciences by 112.7% in the first quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock valued at $42,000 after purchasing an additional 2,195 shares during the period. Russell Investments Group Ltd. grew its holdings in Roivant Sciences by 94.8% in the first quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company's stock valued at $46,000 after purchasing an additional 2,233 shares during the period. Finally, Fifth Third Bancorp grew its holdings in Roivant Sciences by 59.3% in the first quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock valued at $52,000 after purchasing an additional 1,905 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on ROIV shares. Weiss Ratings reiterated a "sell (d+)" rating on shares of Roivant Sciences in a research note on Wednesday. The Goldman Sachs Group increased their price objective on Roivant Sciences from $20.00 to $24.00 and gave the company a "buy" rating in a report on Thursday, September 18th. JPMorgan Chase & Co. increased their price objective on Roivant Sciences from $16.00 to $20.00 and gave the company an "overweight" rating in a report on Thursday, September 18th. Leerink Partners increased their price objective on Roivant Sciences from $18.00 to $22.00 and gave the company an "outperform" rating in a report on Thursday, September 18th. Finally, Citigroup started coverage on Roivant Sciences in a report on Tuesday, September 2nd. They issued a "buy" rating and a $16.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Roivant Sciences has an average rating of "Moderate Buy" and a consensus price target of $19.94.
Read Our Latest Stock Report on Roivant Sciences
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
